GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Inventories, Other

NVS (Novartis AG) Inventories, Other : $5,939 Mil (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Novartis AG's other inventories for the quarter that ended in Sep. 2024 was $5,939 Mil.

Novartis AG's quarterly other inventories increased from Mar. 2024 ($5,743 Mil) to Jun. 2024 ($5,747 Mil) and increased from Jun. 2024 ($5,747 Mil) to Sep. 2024 ($5,939 Mil).


Novartis AG Inventories, Other Historical Data

The historical data trend for Novartis AG's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Inventories, Other Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novartis AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,610.00 - 5,743.00 5,747.00 5,939.00

Novartis AG Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Novartis AG Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.